Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

Sensus Healthcare, Inc.

SRTSNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) On November 10, 2025, the Board of Directors (the “Board”) of Sensus Healthcare, Inc. (the “Company”) appointed Eric Sachetta as a Class II director of the Company for a term expiring at the Company’s annual meeting in 2026. Mr.…

Filed Nov 13, 2025Accepted Nov 13, 2025, 10:06 AM ESTCIK 1494891Accession 0001753926-25-001772
Share

Company context

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Current securities

Historical securities (1)

Recent company filings

  1. 4 filingAug 24, 2026
  2. 10-Q filingAug 14, 2026
  3. Results of Operations and Financial ConditionAug 13, 2026
  4. Entry into a Material Definitive AgreementJun 5, 2026
  5. Submission of Matters to a Vote of Security HoldersJun 2, 2026

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) On November 10, 2025, the Board of Directors (the “Board”) of Sensus Healthcare, Inc. (the “Company”) appointed Eric Sachetta as a Class II director of the Company for a term expiring at the Company’s annual meeting in 2026. Mr. Sachetta fills a vacancy resulting from the death of William McCall. Mr. Sachetta, age 37, is Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm founded by Mr. Sachetta. In that role, his responsibilities include leading and managing the firm’s financial advisory division and overseeing all wealth management operations and advisor development. Before assuming his current position in 2022, he held other positions with the firm from 2016. Mr. Sachetta’s previous employment included serving as a leadership speaker and author and as a district manager of a marketing organization. He is a Certified Financial Planner® and holds other licenses and certifications. Mr. Sachetta received a bachelor’s degree in Corporate Finance and Accounting from Bentley University. There are no arrangements or understandings between Mr. Sachetta and any other persons pursuant to which he was elected, nor does he have any direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Securities and Exchange Commission Regulation S-K. As a director of the Company, Mr. Sachetta is expected to receive the same compensation for service as a director as is provided to other non-employee directors of the Company on a pro-rata annual basis. The Board has determined that Mr. Sachetta is an independent director within the meaning of Rule 5605(a)(2) as set forth in the listing standards of The NASDAQ Stock Market, LLC. Mr. Sachetta has been appointed as a member of the Audit Committee of the Board. On November 12, 2025, the Company issued a press release announcing Mr. Sachetta’s election. The press release is filed as an exhibit to this Report. The press release shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) g085016_ex99-1.htm

EX-99.1 2 g085016_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sensus Healthcare Appoints Eric Sachetta to its Board of Directors Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence BOCA RATON, Fla. (November 12, 2025) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company’s Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operational improvement. He currently serves as Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm based in Lynnfield, Mass., where he leads firmwide advisory strategy, operational oversight, financial planning innovation and multi-disciplinary client service execution. Since 2022, he has led and managed the firm’s fi…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.